Sinn und Unsinn der Anti-Aging Medizin

Bernd Kleine-Gunk

 

  1. Kleine-Gunk B, Metka M, 2010, Auf der Suche nach Unsterblichkeit – Die Geschichte der Anti-Aging Medizin von der Antike bis heute, Wien, Brandstätter Verlag
  2. Klatz R, Goldman B, 2007, The official anti-aging revolution, Laguna Beach, Basic Health Publications
  3. www.worldhealth.net/about-a4m
  4. Klatz R, 1997, Grow young with HGH, New York, William Morrow
  5. Liu H et al, 2007, Systemic review: The safety and efficacy of growth hormone in the healthy elderly. Annals of Internal Medicine, 104–115
  6. Olshansky J, Hayflick L, 2007, Position statement on human aging, Journal of Gerontology: Biological sciences Bd 57AH8, 292–97
  7. Kleine-Gunk B, 2007, Anti-Aging Medizin  - Hoffnung oder Humbug? Dt. Ärzteblatt, Bd 104, A2054–60
  8. Spindler M, 2014, Altern ja – aber gesundes Altern. Die Neubegründung der Anti-Aging Medizin in Deutschland, Wiesbaden, Springer Verlag
  9. Lopez-Otin L et al, 2013, The hallmarks of Aging Cell 153. 1194–1217
  10. Fontana L et al, 2010, Extending healthy life span – from yeast to humans, Science 328, 321–326
  11. de Grey A, Rae M, 2007, Ending Aging: The Rejuvenation Breakthroughs That Could Reverse Human Aging in our Lifetime, New York, Griffin
  12. de Grey A, 2002, Time to talk SENS: Critiquing the Immutability of Human Aging, Annals of the New York Academy of Sciences 959: 452–62
  13. Holliday R, 2009, The extreme arrogance of anti-aging medicine, Biogerontology 10(2): 223–8
  14. Kurzweil R, Grossmann T (2004) Fantastic Voyage: Live long enough to live forever, Rodale Bools
  15. New York Time, Calico versus Death, Sept 18, 2013
  16. Kurzweil R, 2005, The singularity is near: When humans transcend biology, London, Penguin Books
  17. Kurzweil R, 2012, How to create a mind: The secret of human thought research, New York, Viking Adult
  18. Fukuyama F, 2004, Transhumanism: The World´s most dangerous Idea, Foreign Policy 144: 42–43

Perioperative orale/enterale Immunonutrition nach Ernährungsscreening mit Hilfe des Nutritional Risk Screenings bei Patientinnen mit Ovarialkarzinom

Linda Hertlein, Peter Rittler

 

  1. Correia MI, Campos AC. Prevalence of hospital malnutrition in Latin America: the multicenter ELAN study. Nutrition. 2003 Oct;19(10):823-5. PubMed PMID: 14559314. Epub 2003/10/16. eng.
  2. Edington J, Boorman J, Durrant ER, Perkins A, Giffin CV, James R, et al. Prevalence of malnutrition on admission to four hospitals in England. The Malnutrition Prevalence Group. Clin Nutr. 2000 Jun;19(3):191-5. PubMed PMID: 10895110. Epub 2000/07/15. eng.
  3. Naber TH, Schermer T, de Bree A, Nusteling K, Eggink L, Kruimel JW, et al. Prevalence of malnutrition in nonsurgical hospitalized patients and its association with disease complications. Am J Clin Nutr. 1997 Nov;66(5):1232-9. PubMed PMID: 9356543. Epub 1997/11/14. eng.
  4. Waitzberg DL, Caiaffa WT, Correia MI. Hospital malnutrition: the Brazilian national survey (IBRANUTRI): a study of 4000 patients. Nutrition. 2001 Jul-Aug;17(7-8):573-80. PubMed PMID: 11448575. Epub 2001/07/13. eng.
  5. Sorensen J, Kondrup J, Prokopowicz J, Schiesser M, Krahenbuhl L, Meier R, et al. EuroOOPS: an international, multicentre study to implement nutritional risk screening and evaluate clinical outcome. Clin Nutr. 2008 Jun;27(3):340-9. PubMed PMID: 18504063. Epub 2008/05/28. eng.
  6. Pirlich M, Schutz T, Norman K, Gastell S, Lubke HJ, Bischoff SC, et al. The German hospital malnutrition study. Clin Nutr. 2006 Aug;25(4):563-72. PubMed PMID: 16698132. Epub 2006/05/16. eng.
  7. Kondrup J, Rasmussen HH, Hamberg O, Stanga Z. Nutritional risk screening (NRS 2002): a new method based on an analysis of controlled clinical trials. Clin Nutr. 2003 Jun;22(3):321-36. PubMed PMID: 12765673. Epub 2003/05/27. eng.
  8. Kondrup J, Allison SP, Elia M, Vellas B, Plauth M. ESPEN guidelines for nutrition screening 2002. Clin Nutr. 2003 Aug;22(4):415-21. PubMed PMID: 12880610. Epub 2003/07/26. eng.
  9. Hertlein L, Kirschenhofer A, Furst S, Beer D, Goss C, Lenhard M, et al. Malnutrition and clinical outcome in gynecologic patients. European journal of obstetrics, gynecology, and reproductive biology. 2014 Mar;174:137-40. PubMed PMID: 24485666. Epub 2014/02/04. eng.
  10. Senkal M, Zumtobel V, Bauer KH, Marpe B, Wolfram G, Frei A, et al. Outcome and cost-effectiveness of perioperative enteral immunonutrition in patients undergoing elective upper gastrointestinal tract surgery: a prospective randomized study. Arch Surg. 1999 Dec;134(12):1309-16. PubMed PMID: 10593328. Epub 1999/12/11. eng.
  11. Weimann A, Jauch KW, Kemen M, Hiesmayr JM, Horbach T, Kuse ER, Vestweber KH. DGEM-Leitlinie Enterale Ernährung: Chirurgie und Transplantation. Aktuel Ernahr Med 2003.
  12. Weimann A, Breitenstein S, Breuer JP, Gabor SE, Holland-Cunz S, Kemen M, et al. [Clinical nutrition in surgery. Guidelines of the German Society for Nutritional Medicine]. Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen. 2014 Apr;85(4):320-6. PubMed PMID: 24718444. Epub 2014/04/11. Klinische Ernahrung in der Chirurgie. S3-Leitlinie der Deutschen Gesellschaft fur Ernahrungsmedizin e. V. ger.

Hormonsubstitution ab der Menopause reduziert Gesamt-Mortalität

J. M. Wenderlein

 

  1. Sarrel PM et al Am J Public Health. 2013 Jul. [Epuba head of print] LoE II-3  The Mortality Toll of Estrogen Avoidance: An Analysis of Excess Deaths Among Hysterectomized WomenAged 50 to 59 Years
  2. Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health. 1998; 19: 55-–72.
  3. Duan L, Xu X, Koebnick C, et al. Bilateral oophorectomy is not associated with increased mortality: the California Teachers Study. Fertil Steril. 2012; 97(1): 111–117.
  4. Schierbeck LL, Rejnmark L, Tofteng CK, et al. Effect of hormone replacement treatment on cardiovascular events in recently postmenopausal women: randomized trials. BMJ. 2012; 345: e6409
  5. Salpeter SR, Cheng, Thabane L, et al. Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women.Am J Med. 2009; 122(11): 1016–1022.
  6. Salpeter SR, Walsh JM, Greyber E, et al. Mortality associated with hormone replacement therapy in younger and older women: a metaanalysis.J Gen Intern Med. 2004; 19(7): 791–804
  7. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause.JAMA. 2007; 297(13): 1465–1477.
  8. La Croix AZ, Chlebowski RT, Manson JE, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with hysterectomy: a randomized controlled trial. JAMA. 2011; 305(13): 1305–1314.
  9. Clarkson TB, Meléndez GC, Appt SE. Timing hypothesis for postmenopausal hormone therapy: its origin, current status, and future. Menopause2013; 20(3): 342–353
  10. MaosonJA et al:Menopausal Hormone Therpy and Health Outcomes During the  Intervention and Extended Poststopping Phases of theWHI Randomized Trials.JAMA 2013: 310; 1353–1368

Peripartum Kardiomyopathie

Arash Haghikia, Melanie Ricke-Hoch und Denise Hilfiker-Kleiner

 

  1. Sliwa K, Hilfiker-Kleiner D, Petrie MC, Mebazaa A, Pieske B, Buchmann E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. European journal of heart failure 2010; 12: 767–778.
  2. Haghikia A, Podewski E, Libhaber E, Labidi S, Fischer D, Roentgen P, et al. Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy. Basic research in cardiology 2013; 108: 366.
  3. Labidi S, Hilfiker-Kleiner D, Klein G. Left bundle branch block during pregnancy as a sign of imminent peripartum cardiomyopathy. European heart journal 2011; 32: 1076.
  4. Brar SS, Khan SS, Sandhu GK, Jorgensen MB, Parikh N, Hsu JW, et al. Incidence, mortality, and racial differences in peripartum cardiomyopathy. The American journal of cardiology 2007; 100: 302–304.
  5. Fett JD. Peripartum cardiomyopathy. Insights from Haiti regarding a disease of unknown etiology. Minnesota medicine 2002; 85: 46–48.
  6. Fett JD, Christie LG, Carraway RD, Ansari AA, Sundstrom JB, Murphy JG. Unrecognized peripartum cardiomyopathy in Haitian women. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 2005; 90: 161–166.
  7. Sliwa K, Forster O, Libhaber E, Fett JD, Sundstrom JB, Hilfiker-Kleiner D, et al. Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. European heart journal 2006; 27: 441–446.
  8. Kamiya CA, Kitakaze M, Ishibashi-Ueda H, Nakatani S, Murohara T, Tomoike H, et al. Different characteristics of peripartum cardiomyopathy between patients complicated with and without hypertensive disorders. -Results from the Japanese Nationwide survey of peripartum cardiomyopathy. Circulation journal : official journal of the Japanese Circulation Society 2011; 75: 1975–1981.
  9. van Spaendonck-Zwarts KY, Posafalvi A, van den Berg MP, Hilfiker-Kleiner D, Bollen IA, Sliwa K, et al. Titin gene mutations are common in families with both peripartum cardiomyopathy and dilated cardiomyopathy. European heart journal 2014.
  10. Hilfiker-Kleiner D, Kaminski K, Podewski E, Bonda T, Schaefer A, Sliwa K, et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 2007; 128: 589–600.
  11. Patten IS, Rana S, Shahul S, Rowe GC, Jang C, Liu L, et al. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature 2012; 485: 333-338.
  12. Halkein J, Tabruyn SP, Ricke-Hoch M, Haghikia A, Nguyen NQ, Scherr M, et al. MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. The Journal of clinical investigation 2013; 123: 2143 –2154.
  13. Selle T, Renger I, Labidi S, Bultmann I, Hilfiker-Kleiner D. Reviewing peripartum cardiomyopathy: current state of knowledge. Future cardiology 2009; 5: 175–189.
  14. Warraich RS, Sliwa K, Damasceno A, Carraway R, Sundrom B, Arif G, et al. Impact of pregnancy-related heart failure on humoral immunity: clinical relevance of G3-subclass immunoglobulins in peripartum cardiomyopathy. American heart journal 2005; 150: 263–269.
  15. Sliwa K, Skudicky D, Candy G, Bergemann A, Hopley M, Sareli P. The addition of pentoxifylline to conventional therapy improves outcome in patients with peripartum cardiomyopathy. European journal of heart failure 2002; 4: 305–309.
  16. Forster O, Hilfiker-Kleiner D, Ansari AA, Sundstrom JB, Libhaber E, Tshani W, et al. Reversal of IFN-gamma, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy. European journal of heart failure 2008; 10: 861–868.
  17. Sliwa K, Blauwet L, Tibazarwa K, Libhaber E, Smedema JP, Becker A, et al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation 2010; 121: 1465–1473.
  18. Ricke-Hoch M, Bultmann I, Stapel B, Condorelli G, Rinas U, Sliwa K, et al. Opposing roles of Akt and STAT3 in the protection of the maternal heart from peripartum stress. Cardiovascular research 2014; 101: 587–596.
  19. Walenta K, Schwarz V, Schirmer SH, Kindermann I, Friedrich EB, Solomayer EF, et al. Circulating microparticles as indicators of peripartum cardiomyopathy. European heart journal 2012; 33: 1469–1479.
  20. Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, Cifkova R, Ferreira R, Foidart JM, et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 3147–3197.
  21. Anderssohn M, Rosenberg M, Schwedhelm E, Zugck C, Lutz M, Luneburg N, et al. The L-Arginine-asymmetric dimethylarginine ratio is an independent predictor of mortality in dilated cardiomyopathy. Journal of cardiac failure 2012; 18: 904–911.